文献速递白血病

NPM1突变急性髓系白血病早期死亡危险因素分析

[Analysis of risk factors for early death in NPM1-mutated acute myeloid leukemia patients].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性研究纳入405例初诊原发性NPM1突变急性髓系白血病患者,分析诊断时临床及实验室资料。早期死亡35例(8.6%),主要死因为重症感染和出血。多因素分析显示查尔森合并症指数、低血小板计数、凝血功能异常、CD34(-)/HLA-DR(-)免疫表型及重症感染是早期死亡的独立危险因素。

要点

  • NPM1突变AML患者早期死亡率为8.6%,重症感染和出血为主要死因
  • CD34(-)/HLA-DR(-)免疫表型是早期死亡的独立危险因素,应纳入风险分层
  • 查尔森合并症指数、低血小板、凝血异常和重症感染亦为独立危险因素

核心结论

  • 重症感染和出血是NPM1突变AML患者早期死亡的主要危险因素。
  • CD34(-)/HLA-DR(-)免疫表型增加早期死亡风险,应纳入临床管理以指导早期干预。

研究设计与样本

  • 回顾性分析2018年6月至2023年6月苏州大学附属第一医院和盐城市第一人民医院收治的405例初诊原发性NPM1突变AML患者。
  • 分析诊断时临床和实验室资料,采用单因素及多因素Logistic回归探讨早期死亡危险因素。

主要发现

  • 405例患者中位年龄53(14~86)岁,男177例,女228例。
  • 诊断时常见突变为DNMT3A(51.8%)、FLT3-ITD(51.3%)、FLT3-TKD(25.1%)、IDH2(21.5%)和TET2(21.0%)。
  • 早期死亡35例(8.6%),死因包括重症感染14例(40.0%)、脑出血11例(31.4%)、脑梗死4例(11.4%)、肺出血3例(8.6%)。
  • 与非早期死亡组相比,早期死亡组CD34(-)/HLA-DR(-)比例较高(71.4%对30.0%,P<0.001),凝血功能异常发生率较高(80.0%对27.5%,P<0.001),TET2突变发生率较高(40.0%对19.1%,P=0.004)。

关键数值与推荐

  • 多因素分析显示查尔森合并症指数(OR=10.540,P=0.003)、低血小板计数(OR=10.980,P=0.001)、凝血功能异常(OR=7.126,P=0.005)、CD34(-)/HLA-DR(-)免疫表型(OR=6.416,P=0.002)和重症感染(OR=59.080,P<0.001)是早期死亡的独立危险因素。

临床怎么用

  • 对NPM1突变AML患者应评估查尔森合并症指数、血小板计数、凝血功能及CD34(-)/HLA-DR(-)免疫表型以识别早期死亡高危患者。
  • 加强重症感染和出血的预防与早期干预,以降低早期死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the risk factors for early death (ED) in patients with NPM1-mutated acute myeloid leukemia (NPM1(mut) AML) . Methods: A retrospective analysis was conducted on 405 newly diagnosed primary NPM1(mut) AML patients admitted to the First Affiliated Hospital of Soochow University and the First People's Hospital of Yancheng between June 2018 and June 2023. Clinical and laboratory data at diagnosis were analyzed. Univariate and multivariate logistic regression analyses were used to explore the risk factors for early death in these patients. Results: The median age of the 405 NPM1(mut) AML patients was 53 (14-86) years, with 177 males and 228 females. The most common mutations at diagnosis were in DNMT3A (51.8% ), FLT3-ITD (51.3% ), FLT3-TKD (25.1% ), IDH2 (21.5% ), and TET2 (21.0% ). Thirty-five patients (8.6% ) experienced ED, with causes including 14 cases (40.0% ) of severe infection, 11 cases (31.4% ) of cerebral hemorrhage, 4 cases (11.4% ) of cerebral infarction, and 3 cases (8.6% ) of pulmonary hemorrhage. Compared with non-ED patients, ED patients had a significantly higher proportion of the CD34 and HLA-DR double-negative immunophenotype (CD34(-)/HLA-DR(-)) (71.4% vs 30.0%, P<0.001), a higher incidence of coagulopathy (80.0% vs 27.5%, P<0.001), and a higher incidence of TET2 mutations (40.0% vs 19.1%, P=0.004). Multivariate analysis showed that the Charlson comorbidity index (CCI) (OR=10.540, P=0.003), platelet count (OR=10.980, P=0.001), coagulopathy (OR=7.126, P=0.005), CD34(-)/HLA-DR(-) immunophenotype (OR=6.416, P=0.002), and infection (OR=59.080, P<0.001) were independent risk factors for ED in NPM1(mut) AML patients. Conclusion: Severe infection and bleeding were the main risk factors for ED in NPM1(mut) AML patients, and the CD34(-)/HLA-DR(-) immunophenotype should be considered in risk stratification and clinical management of patients with NPM1(mut) AML to guide early intervention. 目的: 探讨伴NPM1突变急性髓系白血病(NPM1(mut) AML)患者早期死亡(ED)的危险因素。 方法: 回顾性分析2018年6月至2023年6月苏州大学附属第一医院和盐城市第一人民医院收治的初诊原发性NPM1(mut) AML患者共405例,对患者诊断时的临床和实验室资料进行分析。应用单因素及多因素Logistic回归分析方法探讨NPM1(mut) AML患者ED的影响因素。 结果: 405例NPM1(mut) AML患者的中位年龄为53(14~86)岁,男177例,女228例,诊断时常见的突变为DNMT3A(51.8%)、FLT3-ITD(51.3%)、FLT3-TKD(25.1%)、IDH2(21.5%)和TET2(21.0%)突变。ED患者35例(8.6%),其中死于重症感染14例(40.0%)、脑出血11例(31.4%)、脑梗死4例(11.4%)、肺出血3例(8.6%)。与非ED患者相比,ED组患者CD34(-)/HLA-DR(-)免疫表型的比例较高(71.4%对30.0%, P<0.001),凝血功能异常发生率较高(80.0%对27.5%, P<0.001),TET2突变发生率较高(40.0%对19.1%, P=0.004)。多因素分析显示查尔森合并症指数(CCI)(OR=10.540, P=0.003)、低血小板计数(OR=10.980, P=0.001)、凝血功能异常(OR=7.126, P=0.005)、CD34(-)/HLA-DR(-)(OR=6.416, P=0.002)和重症感染(OR=59.080, P<0.001)是患者ED的独立危险因素。 结论: 重症感染和出血是NPM1(mut) AML患者ED的主要危险因素,CD34(-)/HLA-DR(-)免疫表型增加了NPM1(mut) AML患者的ED风险,应纳入临床管理中,以指导早期临床干预。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang LL, Shu MK, Dou XQ, et al. [Analysis of risk factors for early death in NPM1-mutated acute myeloid leukemia patients]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161659. doi:10.3760/cma.j.cn121090-20250929-00452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。